The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

Trial Profile

The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Erteberel (Primary) ; Antipsychotics
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Oct 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
    • 09 Oct 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top